The meninges: new therapeutic targets for multiple sclerosis.
暂无分享,去创建一个
[1] N. Thomson,et al. IL-33 induces innate lymphoid cell–mediated airway inflammation by activating mammalian target of rapamycin , 2012, The Journal of allergy and clinical immunology.
[2] R. Tubbs,et al. The pia mater: a comprehensive review of literature , 2013, Child's Nervous System.
[3] A. Baxter,et al. The origin and application of experimental autoimmune encephalomyelitis , 2007, Nature Reviews Immunology.
[4] M. Forrest,et al. Sphingosine-1-Phosphate Receptor Agonism Impairs the Efficiency of the Local Immune Response by Altering Trafficking of Naive and Antigen-Activated CD4+ T Cells , 2003, The Journal of Immunology.
[5] Robert Zivadinov,et al. Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis A 5-year longitudinal study , 2009, Journal of the Neurological Sciences.
[6] S. Maier,et al. A novel immune-to-CNS communication pathway: Cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus , 2007, Brain, Behavior, and Immunity.
[7] S. Rivest,et al. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood–brain barrier , 1999, Neuroscience.
[8] J. Geurts,et al. Meningeal Inflammation is not Associated With Cortical Demyelination in Chronic Multiple Sclerosis , 2009, Journal of neuropathology and experimental neurology.
[9] Wojciech Pawlina,et al. Comprar Histology: A Text and Atlas, 7ª Ed. With Correlated Cell And Molecular Biology | Michael H Ross | 9781469889313 | Lippincott Williams & Wilkins , 2015 .
[10] Jonathan D Rodgers,et al. Characterizing cognitive function during relapse in multiple sclerosis , 2014, Multiple sclerosis.
[11] R. Voskuhl,et al. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. , 1997, Journal of immunology.
[12] R. Kuzniecky,et al. An implantable triple-function device for local drug delivery, cerebrospinal fluid removal and EEG recording in the cranial subdural/subarachnoid space of primates , 2012, Journal of Neuroscience Methods.
[13] D. Metcalfe,et al. Induction and enhancement of Fc(epsilon)RI-dependent mast cell degranulation following coculture with activated T cells: dependency on ICAM-1- and leukocyte function-associated antigen (LFA)-1-mediated heterotypic aggregation. , 1998, Journal of immunology.
[14] S. Amor,et al. Abundant extracellular myelin in the meninges of patients with multiple sclerosis , 2009, Neuropathology and applied neurobiology.
[15] Alberto Romagnolo,et al. Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: A neuropathological study , 2008, Journal of Neuroimmunology.
[16] Lawrence Steinman,et al. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis , 2006, Annals of neurology.
[17] J. Parisi,et al. Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination. , 2011, Archives of neurology.
[18] B. Becher,et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis , 2005, Nature Medicine.
[19] H. Weiner,et al. Role of Mast Cells in Peripheral Nervous System Demyelination , 1988, Annals of the New York Academy of Sciences.
[20] T. Pufe,et al. Expression and regulation of antimicrobial peptide rCRAMP after bacterial infection in primary rat meningeal cells , 2009, Journal of Neuroimmunology.
[21] B. Bielekova,et al. Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis , 2012, Science Translational Medicine.
[22] D. Linthicum,et al. Mast cell‐derived histamine and tumour necrosis factor: Differences between SJL/J and BALB/c inbred strains of mice , 1996, Immunology and cell biology.
[23] W. Ouyang,et al. A role for Th17 cells in the regulation of tertiary lymphoid follicles , 2012, European journal of immunology.
[24] M. Simons,et al. Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies , 2010, Current neuropharmacology.
[25] D. Arnold,et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis , 2014, Journal of Neurology.
[26] C. Gasperini,et al. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies , 2013, Expert opinion on investigational drugs.
[27] H. Wekerle,et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions , 2009, Nature.
[28] D. Wakefield,et al. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. , 1998, The Journal of clinical investigation.
[29] W. Reith,et al. TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. , 2006, Brain : a journal of neurology.
[30] H. Hartung,et al. Animal models of multiple sclerosis—Potentials and limitations , 2010, Progress in Neurobiology.
[31] R. Ransohoff. Immunology: In the beginning , 2009, Nature.
[32] R. Reynolds,et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.
[33] Lisbeth Illum,et al. Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.
[34] A. Vandenbark,et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. , 1999, Journal of immunology.
[35] C. Polman,et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS , 2004, Neurology.
[36] R. Reynolds,et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.
[37] A. Reder,et al. The mast cells of the multiple sclerosis brain , 1996, Journal of Neuroimmunology.
[38] B. Melchior,et al. CNS immune privilege: hiding in plain sight , 2006, Immunological reviews.
[39] V. ter meulen,et al. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[40] R. Voskuhl,et al. Sex Hormones in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis , 2001, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[41] G. Anderson,et al. OX40 and CD30 signals in CD4+ T‐cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T‐cell memory but not effector function , 2011, Immunological reviews.
[42] R. Reynolds,et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.
[43] R. Ransohoff,et al. Localizing central nervous system immune surveillance: Meningeal antigen‐presenting cells activate T cells during experimental autoimmune encephalomyelitis , 2009, Annals of neurology.
[44] J. Parisi,et al. A case of multiple sclerosis presenting with inflammatory cortical demyelination , 2011, Neurology.
[45] J. Tigges,et al. Subarachnoid space of the CNS, nasal mucosa, and lymphatic system. , 1979, Archives of otolaryngology.
[46] Melissa A Brown,et al. The master switch: the role of mast cells in autoimmunity and tolerance. , 2008, Annual review of immunology.
[47] L. Tuomisto,et al. Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis , 1983, Agents and Actions.
[48] M. Krampera,et al. Meninges: from protective membrane to stem cell niche. , 2012, American journal of stem cells.
[49] F. Safavi,et al. The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF , 2011, Nature Immunology.
[50] R. Ransohoff,et al. Human cerebrospinal fluid central memory CD4+ T cells: Evidence for trafficking through choroid plexus and meninges via P-selectin , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[51] Dongmei Sun,et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[52] P. Ascierto,et al. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.
[53] M. Khorramizadeh,et al. Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. , 2014, Iranian journal of allergy, asthma, and immunology.
[54] S. Hauser,et al. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients , 1995, Annals of neurology.
[55] C. Weyand,et al. Ectopic Germinal Center Formation in Rheumatoid Synovitis , 2003, Annals of the New York Academy of Sciences.
[56] M. H. Ross,et al. Histology: A Text and Atlas , 1985 .
[57] Jorge R. Oksenberg,et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.
[58] M. Bynoe,et al. A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis , 2012, The Journal of Immunology.
[59] P. O'Connor. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. , 2007, Expert opinion on biological therapy.
[60] H. Weiner,et al. The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation , 1988, Brain Research.
[61] W. Banks,et al. Intranasal Administration as a Route for Drug Delivery to the Brain: Evidence for a Unique Pathway for Albumin , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[62] W. Aulitzky,et al. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™) , 2008, Therapeutics and clinical risk management.
[63] C. Gutekunst,et al. Mast Cells Are Essential for Early Onset and Severe Disease in a Murine Model of Multiple Sclerosis , 2000, The Journal of experimental medicine.
[64] Richard Reynolds,et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. , 2013, Brain : a journal of neurology.
[65] S. Hauser,et al. The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.
[66] P. O'Connor. Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis , 2007 .
[67] Melissa A Brown,et al. Mast Cells , 2008, Annals of the New York Academy of Sciences.
[68] B. Engelhardt,et al. C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE , 2009, Nature Immunology.
[69] A. McKenzie,et al. Innate lymphoid cells — how did we miss them? , 2013, Nature Reviews Immunology.
[70] Simon C. Potter,et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.
[71] D. Hinrichs,et al. Mast cell proteases liberate stable encephalitogenic fragments from intact myelin. , 1991, Cellular immunology.
[72] B. Becher,et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.
[73] R. Reynolds,et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. , 2012, Brain : a journal of neurology.
[74] J. Quevedo,et al. Inhibition of indoleamine 2,3-dioxygenase prevented cognitive impairment in adult Wistar rats subjected to pneumococcal meningitis. , 2013, Translational research : the journal of laboratory and clinical medicine.
[75] Hartwig Wolburg,et al. Choroid plexus: biology and pathology , 2009, Acta Neuropathologica.
[76] M. E. Walker,et al. Cutting Edge: Mast Cells Regulate Disease Severity in a Relapsing–Remitting Model of Multiple Sclerosis , 2011, The Journal of Immunology.
[77] D. J. Neumann. Ueber das Vorkommen der sogenannten „Mastzellen” bei pathologischen Veränderungen des Gehirns , 1890, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.
[78] I. McGregor,et al. The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis , 2014, Brain, Behavior, and Immunity.
[79] M. Oukka,et al. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism , 2013, Mucosal Immunology.
[80] R. Reynolds,et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords , 2010, Annals of neurology.
[81] Sumana Chakravarty,et al. Toll-Like Receptor 4 on Nonhematopoietic Cells Sustains CNS Inflammation during Endotoxemia, Independent of Systemic Cytokines , 2005, The Journal of Neuroscience.
[82] R. Friede,et al. The origin of subdural neomembranes. I. Fine structure of the dura-arachnoid interface in man. , 1978, The American journal of pathology.
[83] E. Fabbretti,et al. Mast cell activation by myelin through scavenger receptor , 2008, Journal of Neuroimmunology.
[84] P. Robbins,et al. Induction of pregnancy during established EAE halts progression of CNS autoimmune injury via pregnancy-specific serum factors , 2011, Journal of Neuroimmunology.
[85] P. Nichelli,et al. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM , 2011, Multiple sclerosis.
[86] J. Geurts,et al. Gray matter imaging in multiple sclerosis: what have we learned? , 2011, BMC neurology.
[87] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.
[88] C. V. Jensen,et al. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis , 2001, European journal of neurology.
[89] H. Hartung,et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis , 2013, Neurology.
[90] C. Whitacre. Sex differences in autoimmune disease , 2001, Nature Immunology.
[91] K. Peterson,et al. TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. , 2011, The American journal of pathology.
[92] R. Ransohoff,et al. Animal models of multiple sclerosis: the good, the bad and the bottom line , 2012, Nature Neuroscience.
[93] D. Hinrichs,et al. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. , 1989, Journal of immunology.
[94] Ondrej Dolezal,et al. Clinical correlates of grey matter pathology in multiple sclerosis , 2012, BMC Neurology.
[95] J. Foley,et al. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action , 2013, Biologics : targets & therapy.
[96] R. Dantzer,et al. Interleukin-10 in the brain. , 2001, Critical reviews in immunology.
[97] P. Sawchenko,et al. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis , 2007, The Journal of comparative neurology.
[98] M. Hessner,et al. Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE. , 2013, Journal of autoimmunity.
[99] Rohit Bakshi,et al. Gray matter involvement in multiple sclerosis , 2007, Neurology.
[100] M. Tsai,et al. Mast Cells Enhance T Cell Activation: Importance of Mast Cell Costimulatory Molecules and Secreted TNF1 , 2006, The Journal of Immunology.
[101] Eric Vivier,et al. Innate lymphoid cells — a proposal for uniform nomenclature , 2013, Nature Reviews Immunology.
[102] R. Weller. Microscopic morphology and histology of the human meninges. , 2005, Morphologie : bulletin de l'Association des anatomistes.
[103] Yukihiko Kitamura,et al. Decrease of mast cells in w/wv mice and their increase by bone marrow transplantation. , 1978 .
[104] W. Ong,et al. Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. , 2014, Current medicinal chemistry.
[105] S. Gold,et al. Estrogen and testosterone therapies in multiple sclerosis. , 2009, Progress in brain research.
[106] H. Ovadia,et al. Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis , 2013, Journal of Neuroimmunology.
[107] B. Serafini,et al. Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.
[108] Melinda Fitzgerald,et al. Immunol. Cell Biol. , 1995 .
[109] R. Reynolds,et al. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. , 2010, Brain : a journal of neurology.
[110] O. Kirmi,et al. Anatomy and imaging of the normal meninges. , 2009, Seminars in ultrasound, CT, and MR.
[111] A. Coles. Alemtuzumab Therapy for Multiple Sclerosis , 2012, Neurotherapeutics.
[112] U. Wagner,et al. The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. , 1998, Journal of immunology.
[113] H. Gerber,et al. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. , 2009, Advances in experimental medicine and biology.
[114] John T. Chang,et al. Inducible MHC Class II Expression by Mast Cells Supports Effector and Regulatory T Cell Activation 1 , 2009, The Journal of Immunology.
[115] S. Mahurkar,et al. Identification of Shared Genes and Pathways: A Comparative Study of Multiple Sclerosis Susceptibility, Severity and Response to Interferon Beta Treatment , 2013, PloS one.
[116] Leah M. Alabanza,et al. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis , 2012, Journal of Neuroinflammation.
[117] S. Travis,et al. IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.
[118] David Artis,et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus , 2011, Nature Immunology.
[119] P. Calabresi,et al. Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases , 2005, Molecular Pharmacology.
[120] A. Minagar,et al. The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis , 2005, CNS drugs.
[121] Jiwon Oh,et al. Teriflunomide for the Treatment of Multiple Sclerosis , 2013, Seminars in Neurology.
[122] P. Sawchenko,et al. Type 1 interleukin‐1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL‐1–induced cellular activation , 1995, The Journal of comparative neurology.
[123] P. Maher,et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation , 2012, Journal of Neuroinflammation.
[124] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.
[125] B. Solomon,et al. Antigen-specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope , 2010, Journal of Neuroimmunology.
[126] G. I. Hatton,et al. Anatomy of the brain neurogenic zones revisited: Fractones and the fibroblast/macrophage network , 2002, The Journal of comparative neurology.
[127] R. Kuzniecky,et al. Autoradiographic evidence for the transmeningeal diffusion of muscimol into the neocortex in rats , 2012, Brain Research.
[128] Leah M. Feazel,et al. Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity , 2013, Science.
[129] S. Jalkanen,et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis , 2008, Proceedings of the National Academy of Sciences.
[130] B. Weinshenker,et al. Multiple sclerosis. , 2000, The New England journal of medicine.
[131] M. Juan,et al. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. , 2001, The American journal of pathology.
[132] M Rovaris,et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.
[133] Hans Lassmann,et al. Multiple sclerosis and Alzheimer's disease , 2008, Annals of neurology.
[134] C. Whitacre,et al. Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains , 2004, Journal of Neuroimmunology.
[135] E. Fish. The X-files in immunity: sex-based differences predispose immune responses , 2008, Nature Reviews Immunology.
[136] M. Dwyer,et al. Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.
[137] B. Scheithauer,et al. Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.
[138] P. Calabresi,et al. Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis , 2012, The Journal of Immunology.
[139] K. Dev,et al. The structure and function of the S1P1 receptor. , 2013, Trends in pharmacological sciences.
[140] J. Gauldie,et al. IFN-γ-Induced Chemokines Synergize with Pertussis Toxin to Promote T Cell Entry to the Central Nervous System1 , 2007, The Journal of Immunology.
[141] F. Patti,et al. Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI , 2014, Multiple sclerosis international.
[142] A. Bar-Or,et al. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis , 2014, Drugs.
[143] Hernández-Pando Rogelio,et al. Pathogenesis and immune response in tuberculous meningitis. , 2014, The Malaysian journal of medical sciences : MJMS.
[144] R. Ravid,et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system , 2002, Journal of Neuroimmunology.
[145] M. E. Walker,et al. Meningeal Mast Cells Affect Early T Cell Central Nervous System Infiltration and Blood-Brain Barrier Integrity through TNF: A Role for Neutrophil Recruitment? , 2010, The Journal of Immunology.
[146] C. Lucchinetti,et al. Meningeal and cortical grey matter pathology in multiple sclerosis , 2012, BMC Neurology.
[147] G. Wahl,et al. Mechanism of action for leflunomide in rheumatoid arthritis. , 1999, Clinical immunology.